Pfizer to Pay $345 Million to Exit EpiPen Price-Gouging Case (3)

Pfizer Inc. and two subsidiaries will pay $345 million to escape antitrust litigation over an alleged scheme to gouge purchasers of the EpiPen, a lifesaving allergy treatment formerly made by a Pfizer unit and marketed by Mylan NV, according to a federal court filing in Kansas.

The proposed settlement, filed late Wednesday in the U.S. District Court for the District of Kansas, would resolve class action claims brought against Pfizer on behalf of “end payers” like insurers, pension funds, and consumers that have targeted the two drug giants.

The deal doesn’t directly affect a parallel proposed class action moving ...